During this meeting the consortium presented it’s progress and several postdocs and PhD-students  have shown their research. Day 1 we  had a lecture by keynote speaker Dr. Ali Ellebedy titled The human B cell response to SARS-CoV-2 and COVID-19 vaccination.

Program day 1

10:30 -11:00           Registration

11:00                     Welcome (Cécile van Els)

Update from the WPs; progress and deliverables  (time is including discussion time):

Chair: Maaike Braham

11:10 -11:40            WP1

11:40 – 12:10           WP2/5

12:10 – 12:30           WP4

12:30 – 13:30           Lunch

Chair: Jelle de Wit

13:30 – 14:00           WP3/6

14:00 – 14.30           WP7

14:30 – 15:00           WP8

15:00 – 15:40           ImmuneHealthXL update & Discussion (Marieke van Ham)

15:40 – 16:00           Break

 Keynote lecture

Chair: Cécile van Els

16:00- 17:00           “Human B cell response to SARS-CoV-2” Dr. Ali Ellebedy  (Washington University School Medicine St.Louis, USA , i.e. 09.00 – 10.00 AM CDT) (45’ talk, 15’ Q&A’s)

 17:00                     Drinks

 18:00                     Optional: dinner together at PK Bar & Kitchen in Bilthoven, registration in advance, organization by RIVM

Program day 2

New T2B activities

09:00 – 09:05           Opening (Cécile van Els)

09:05 – 09:20           The B cell epigenome in health and disease (Rudi Hendriks)

09:20 – 09:35           Creating a comprehensive catalogue of disease-associated glycosylation patterns (Jana Koers)

09:35 – 09:50           In situ imaging of rare antigen specific B-cells (Renee van de Wetering)

Regular T2B projects

09:50 – 10:05           In vitro anti-glycolipid antibody production by Guillain-Barré syndrome patients’ derived B cells (Ruth Huizinga, WP2/5)

10:05 – 10:20           Elevated IgA in RA: implications for the mucosal origin hypothesis (Veerle Derksen, WP3/6)

10:20 – 10:35           Rewiring of B cell receptor signaling in response to prolonged kinase inhibitor treatment in mice and man (Stefan Neys, WP7/8)

 10:30 – 10:50           Break

 T2B COVID-19 studies

10:50 – 12:35           Overarching introduction to the T2B COVID-19 (infection and vaccination) studies (max 15’ + 5’ Q&A) (Filip Eftimov)

followed by short result pitches (max 8’+ 4’ Q&A per pitch)

– Biomarkers in Covid 19 infection (Taco Kuijpers)

– Side Effects upon Vaccination (Laura Kummer)

    – Serology tests: the essentials (Maurice Steenhuis)

     – Antibody response in the T2B cohort (Koos van Dam)

– Vaccination and response in MS (Zoé van Kempen)

       – Deep phenotyping upon COVID vaccination (Niels Verstegen)

Closing remarks

12:35 – 12:45           Closing remarks Advisory Board / Patient Organisations

12:45                     Closing Symposium

12:45 – 16:00           –Lunchbox (for those registered)

-Optional break-out sessions for WPs or collaborators can be held, in lecture hall and central hall